Share Email Print
cover

Proceedings Paper

Imaging enabled platforms for development of therapeutics
Author(s): Jonathan Celli; Imran Rizvi; Adam R Blanden; Conor L. Evans; Adnan O. Abu-Yousif; Bryan Q. Spring; Alona Muzikansky; Brian W. Pogue; Dianne M. Finkelstein; Tayyaba Hasan
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Advances in imaging and spectroscopic technologies have enabled the optimization of many therapeutic modalities in cancer and noncancer pathologies either by earlier disease detection or by allowing therapy monitoring. Amongst the therapeutic options benefiting from developments in imaging technologies, photodynamic therapy (PDT) is exceptional. PDT is a photochemistry-based therapeutic approach where a light-sensitive molecule (photosensitizer) is activated with light of appropriate energy (wavelength) to produce reactive molecular species such as free radicals and singlet oxygen. These molecular entities then react with biological targets such as DNA, membranes and other cellular components to impair their function and lead to eventual cell and tissue death. Development of PDT-based imaging also provides a platform for rapid screening of new therapeutics in novel in vitro models prior to expensive and labor-intensive animal studies. In this study we demonstrate how an imaging platform can be used for strategizing a novel combination treatment strategy for multifocal ovarian cancer. Using an in vitro 3D model for micrometastatic ovarian cancer in conjunction with quantitative imaging we examine dose and scheduling strategies for PDT in combination with carboplatin, a chemotherapeutic agent presently in clinical use for management of this deadly form of cancer.

Paper Details

Date Published: 16 February 2011
PDF: 8 pages
Proc. SPIE 7910, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications III, 791002 (16 February 2011); doi: 10.1117/12.877293
Show Author Affiliations
Jonathan Celli, Wellman Ctr. for Photomedicine, Massachusetts General Hospital, Harvard School of Medicine (United States)
Imran Rizvi, Wellman Ctr. for Photomedicine, Massachusetts General Hospital, Harvard School of Medicine (United States)
Dartmouth College (United States)
Adam R Blanden, Wellman Ctr. for Photomedicine, Massachusetts General Hospital, Harvard School of Medicine (United States)
State Univ. of New York (United States)
Conor L. Evans, Wellman Ctr. for Photomedicine, Massachusetts General Hospital, Harvard School of Medicine (United States)
Adnan O. Abu-Yousif, Wellman Ctr. for Photomedicine, Massachusetts General Hospital, Harvard School of Medicine (United States)
Bryan Q. Spring, Wellman Ctr. for Photomedicine, Massachusetts General Hospital, Harvard School of Medicine (United States)
Alona Muzikansky, Biostatistics Ctr., Massachusetts General Hospital (United States)
Brian W. Pogue, Dartmouth College (United States)
Dianne M. Finkelstein, Biostatistics Ctr., Massachusetts General Hospital (United States)
Tayyaba Hasan, Wellman Ctr. for Photomedicine, Massachusetts General Hospital, Harvard School of Medicine (United States)


Published in SPIE Proceedings Vol. 7910:
Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications III
Samuel Achilefu; Ramesh Raghavachari, Editor(s)

© SPIE. Terms of Use
Back to Top